Candel Therapeutics (CADL) EPS (Weighted Average and Diluted) (2021 - 2025)

Candel Therapeutics has disclosed EPS (Weighted Average and Diluted) across 5 years of filings, most recently posting -$0.55 for Q4 2025.

• EPS (Weighted Average and Diluted) for Q4 2025 came in at -$0.55, down 41.03% year-over-year; the trailing twelve-month figure through Dec 2025 was -$0.72 (up 58.62% YoY), and the FY2025 annual result was -$0.72, up 58.62% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.55 for Q4 2025 at Candel Therapeutics, down from -$0.21 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.51 in Q4 2021 to a low of -$1.46 in Q2 2021.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.3 (2022), against an average of -$0.32.
• Across the five-year window, EPS (Weighted Average and Diluted) slumped 900.0% in 2023 and jumped 146.43% in 2025, its largest moves.
• Candel Therapeutics' EPS (Weighted Average and Diluted) stood at $0.51 in 2021, then plunged by 133.33% to -$0.17 in 2022, then plunged by 123.53% to -$0.38 in 2023, then slipped by 2.63% to -$0.39 in 2024, then slumped by 41.03% to -$0.55 in 2025.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.55 (Q4 2025), -$0.21 (Q3 2025), and -$0.09 (Q2 2025), per Business Quant data.